Abstract: In a vehicle diagnostic method and an external diagnostic device, the acceleration of a vehicle is detected while the vehicle is travelling with an acceleration detection means that is provided to the external diagnostic device mounted on the vehicle, and the external diagnostic device acquires operation information of the vehicle from the vehicle. The external diagnostic device performs at least one of a vehicle performance diagnosis, a driving technique diagnosis of the driver, and a fault diagnosis using the operation information and the acceleration of the vehicle.

Abstract: In an external diagnosis device, a vehicle diagnosis method and a vehicle diagnosis system, when an IGSW is on, power is supplied from a vehicle-mounted power supply to the external diagnosis device, and a capacitor provided on the external diagnosis device is charged, and when the IGSW is turned off, the power supply from the vehicle-mounted power supply to the external diagnosis device is stopped, and power is supplied from the capacitor to the external diagnosis device.

Abstract: A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided.

Abstract: In a vehicle diagnostic method and an external diagnostic device, sensor detection values acquired by communicating with an ECU are measured to determine whether the values are in a normal range while a vehicle is idling. After an engine is started, an operation to measure soundness is prohibited at least until the sensor detection values including the engine rotational frequency reach a threshold value region indicating the completion of the warm-up operation. The fluctuation state of the sensor detection values is displayed on an operation screen until the sensor detection values reach the threshold value region.

Abstract: An external diagnosis device, vehicle diagnosis system and vehicle diagnosis method assess the degree of degradation of a vehicle for diagnosis in relation to items for diagnosis, by comparing: multiple threshold values that, for items for diagnosis that are mutually identical, have been set in accordance with the degree of aging of the vehicle for diagnosis, and have been set in relation to the degree of degradation of said vehicle for diagnosis; and a sensor detection value acquired from the vehicle for diagnosis.

Abstract: In an external diagnosis device, a vehicle diagnosis method and a vehicle diagnosis system, when an IGSW is on, power is supplied from a vehicle-mounted power supply to the external diagnosis device, and a capacitor provided on the external diagnosis device is charged, and when the IGSW is turned off, the power supply from the vehicle-mounted power supply to the external diagnosis device is stopped, and power is supplied from the capacitor to the external diagnosis device.

Abstract: In a vehicle diagnostic method and an external diagnostic device, the acceleration of a vehicle is detected while the vehicle is travelling with an acceleration detection means that is provided to the external diagnostic device mounted on the vehicle, and the external diagnostic device acquires operation information of the vehicle from the vehicle. The external diagnostic device performs at least one of a vehicle performance diagnosis, a driving technique diagnosis of the driver, and a fault diagnosis using the operation information and the acceleration of the vehicle.

Abstract: In a vehicle diagnostic method and an external diagnostic device, sensor detection values acquired by communicating with an ECU are measured to determine whether the values are in a normal range while a vehicle is idling. After an engine is started, an operation to measure soundness is prohibited at least until the sensor detection values including the engine rotational frequency reach a threshold value region indicating the completion of the warm-up operation. The fluctuation state of the sensor detection values is displayed on an operation screen until the sensor detection values reach the threshold value region.

Abstract: A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided.

Abstract: The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases. A 4-isopropylphenyl glucitol compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 represents a hydrogen atom, etc., R2 represents a methyl group, etc., R3 represents a C1-4 alkyl group substituted with an amino group(s), etc., and R4 represents a hydrogen atom, etc.

Abstract: C-phenyl 1-thioglucitol compounds of the following formula (I) or pharmaceutically acceptable salts thereof or hydrates thereof: [wherein X represents a hydrogen atom or a C1-6 alkyl group, Y represents a C1-6 alkylene group or —O—(CH2)n- (wherein n represents an integer of 1 to 5), and Z represents —CONHRA or —NHCONHRB (provided that when Z represents —NHCONHRB, n is not 1), wherein RA represents a C1-6 alkyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxyl group and —CONH2, and RB represents a hydrogen atom or a C1-6 alkyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxyl group and —CONH2] are useful as prophylactic or therapeutic agents for diabetes, because of their suppressive effect on sugar (e.g., glucose) absorption through inhibition of SGLT1 activity, or alternatively, because of their suppressive effect on sugar (e.g.

Abstract: Data driver modules are connected to a driver controller. In driver-data output clock selection sections and driver data control sections, each equal in number to the data driver modules that are connected to the driver controller, the phase of driver data is adjusted for each data driver module, while the phase of each driver clock is adjusted in driver-clock output clock selection sections and driver clock control sections.

Abstract: The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases. A 4-isopropylphenyl glucitol compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 represents a hydrogen atom, etc., R2 represents a methyl group, etc., R3 represents a C1-4 alkyl group substituted with an amino group(s), etc., and R4 represents a hydrogen atom, etc.

Abstract: The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceutical comprising such a compound as an active ingredient, especially, a pharmaceutical for preventing or treating diabetes, diabetes-related disease, or diabetic complication. The invention also provides a method for producing the 1-thio-D-glucitol compound and its intermediate.

Abstract: Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action.

Abstract: The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceutical comprising such a compound as an active ingredient, especially, a pharmaceutical for preventing or treating diabetes, diabetes-related disease, or diabetic complication. The invention also provides a method for producing the 1-thio-D-glucitol compound and its intermediate.

Abstract: The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceutical comprising such a compound as an active ingredient, especially, a pharmaceutical for preventing or treating diabetes, diabetes-related disease, or diabetic complication. The invention also provides a method for producing the 1-thio-D-glucitol compound and its intermediate.

Abstract: A 1-phenyl 1-thio-D-glucitol compound represented by formula (I) or the like: or a pharmaceutically acceptable salt thereof or a hydrate thereof, or a pharmaceutical preparation comprising the same as an active ingredient is useful as a novel type of prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which inhibits both SGLT1 and SGLT2 activities to achieve not only suppression of glucose absorption from the digestive tract but also excretion of urinary sugars.

Abstract: Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action.

Abstract: C-phenyl 1-thioglucitol compounds of the following formula (I) or pharmaceutically acceptable salts thereof or hydrates thereof: [wherein X represents a hydrogen atom or a C1-6 alkyl group, Y represents a C1-6 alkylene group or —O—(CH2)n- (wherein n represents an integer of 1 to 5), and Z represents —CONHRA or —NHCONHRB (provided that when Z represents —NHCONHRB, n is not 1), wherein RA represents a C1-6 alkyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxyl group and —CONH2, and RB represents a hydrogen atom or a C1-6 alkyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxyl group and —CONH2] are useful as prophylactic or therapeutic agents for diabetes, because of their suppressive effect on sugar (e.g., glucose) absorption through inhibition of SGLT1 activity, or alternatively, because of their suppressive effect on sugar (e.g.